Summary of EGFR-Biomarker data from the randomized, controlled phase 3 trial SQUIRE on adding Necitumumab to first-line Gemcitabine-Cisplatin (GC) for squamous Non-Small Cell Lung Cancer (sqNSCLC).
Authors
Schumann, CReck, M
Thomas, M
Mezger, J
Socinski, M
Hozak, R
Depenbrock, H
Krause, T
Hirsch, F
Thatcher, Nick
Affiliation
Klinikum Kempten, Pneumol Thoraxonkol Schlaf & Beatmungsmed, Kempten, GermanyIssue Date
2017